Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00407
|
|||||
| Drug Name |
Nateglinide
|
|||||
| Synonyms |
(2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid; A-4166; AY-4166; DJN 608; DJN-608; Fastic; IPCCPA; N-((4-isopropylcyclohexyl)carbonyl)phenylalanine; N-{[4-(propan-2-yl)cyclohexyl]carbonyl}phenylalanine; N-{[trans-4-(propan-2-yl)cyclohexyl]carbonyl}-D-phenylalanine; Nate-glinide; Nateglinide [INN]; Nateglinide, (D-Phe)-isomer; Nateglinide, (cis,D-Phe)-isomer; Novartis brand of nateglinide; SDZ-DJN-608; Senaglinide; Starlix; Starlix (TN); Starsis; Trazec; YM-026
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Diabetes [ICD11:5A10-5A14] | Approved | [1] | |||
| Therapeutic Class |
Hypoglycemic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H27NO3
|
|||||
| Canonical SMILES |
CC(C)C1CCC(CC1)C(=O)NC(CC2=CC=CC=C2)C(=O)O
|
|||||
| InChI |
InChI=1S/C19H27NO3/c1-13(2)15-8-10-16(11-9-15)18(21)20-17(19(22)23)12-14-6-4-3-5-7-14/h3-7,13,15-17H,8-12H2,1-2H3,(H,20,21)(H,22,23)/t15?,16?,17-/m1/s1
|
|||||
| InChIKey |
OELFLUMRDSZNSF-OFLPRAFFSA-N
|
|||||
| CAS Number |
CAS 105816-04-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 317.4 | Topological Polar Surface Area | 66.4 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
3.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103206766
,104253649
,114155796
,117890894
,12013966
,124658899
,124757828
,124801358
,125164632
,126630653
,126657177
,128797137
,128797139
,128797141
,131293719
,131347903
,131860350
,135692483
,136949105
,137129256
,137175459
,137231395
,140330680
,142491149
,142619974
,143248460
,144204985
,14752539
,14874578
,151981031
,152100318
,26719880
,37101837
,39341005
,46386701
,46504836
,49681657
,49830241
,56313768
,57359430
,582898
,75919327
,7848174
,7980094
,81092826
,91748929
,92308370
,92308686
,92711649
,93166415
|
|||||
| ChEBI ID |
ChEBI:31897
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MCT6 | Transporter Info | Monocarboxylate transporter 6 | Substrate | [2] | |
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [3] | ||
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [4] | ||
| References | ||||||
| 1 | Nateglinide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936. | |||||
| 3 | Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334. | |||||
| 4 | FDA Drug Development and Drug Interactions | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.